Virginie Monteilhet

Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.

C. Leborgne, S. Boutin, O. Benveniste, 2010, Human gene therapy.

Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products.

J. Davoust, O. Danos, Laetitia van Wittenberghe, 2006, Blood.

Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors

C. Leborgne, S. Boutin, P. Véron, 2012, The Journal of Immunology.

A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8.

C. Leborgne, S. Boutin, O. Benveniste, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide

J. Davoust, F. Lemonnier, A. Kichler, 2019, Scientific Reports.

Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors

C. Leborgne, S. Boutin, P. Véron, 2012, The Journal of Immunology.